Paysign Inc

Paysign, Inc. (NASDAQ: PAYS) is a provider of prepaid card programs, patient affordability offerings, digital banking services and integrated payment processing designed for businesses, consumers and government institutions. The Company’s payment solutions are utilized by its corporate customers to increase customer loyalty, increase patient adherence rates, reduce administration costs and streamline operations. 

Recent Business and Financial Updates

• Financial Performance Overview for Paysign, Inc. in Q1 2025: Paysign, Inc. (NASDAQ: PAYS), a prominent provider of prepaid card programs, patient affordability solutions, digital banking, and payment processing services, announced its financial results for the first quarter of 2025 on May 8, 2025, reporting total revenues of USD 18.60 million, a 41.0% increase from USD 13.19 million in Q1 2024. Net income rose significantly to USD 2.59 million, or USD 0.05 per diluted share, compared to USD 309 thousand, or USD 0.01 per diluted share, in the prior year, while Adjusted EBITDA surged 193.3% to USD 4.96 million, or USD 0.09 per diluted share, from USD 1.69 million, driven by robust growth in its patient affordability business. Gross profit margins expanded by 10.3 percentage points to 62.9%, reflecting a higher revenue mix from patient affordability programs, despite a 9.2% decline in plasma revenue due to industry-wide oversupply challenges.
• Growth in Patient Affordability and Plasma Operations: The patient affordability segment demonstrated exceptional performance, with revenues increasing 260.8% to USD 8.62 million in Q1 2025 from USD 2.39 million in Q1 2024, fueled by the addition of 14 net programs, bringing the total to 90 active programs, and a 160% rise in processed claims. In contrast, plasma operations saw a revenue decline of 9.2% to USD 9.46 million, attributed to a decrease in revenue per plasma center to USD 6,517 from USD 7,414, despite a net increase of four plasma centers, totaling 484 by quarter-end. This decline was primarily due to reduced plasma donations and an industry-wide oversupply, which also contributed to a 4.5% and 9.4% decrease in gross dollar load volume and gross spend volume, respectively, compared to Q1 2024.
• Operational Efficiency and Cost Management: Paysign achieved significant operational improvements, with gross profit increasing 68.5% to USD 11.70 million from USD 6.95 million in Q1 2024, driven by the high-margin patient affordability business. Cost of revenues rose by 10.5% to USD 6.90 million, reflecting increased customer care expenses of USD 379 thousand and third-party program management fees of USD 366 thousand, though mitigated by reduced network fees and postage costs. Selling, general, and administrative expenses grew by 25.2% to USD 7.39 million, primarily due to a USD 1.54 million increase in compensation costs to support growth, while depreciation and amortization expenses rose 40.0% to USD 1.80 million, reflecting ongoing platform enhancements, contributing to the company’s ability to deliver record operating income.
• Strategic Initiatives and Financial Position: Paysign concluded Q1 2025 with a solid financial position, holding USD 6.85 million in unrestricted cash and no bank debt, despite a USD 3.92 million decrease in unrestricted cash due to the Gamma Innovation acquisition and a repurchase of 100,000 shares for USD 376 thousand. The acquisition is expected to yield annual cash cost savings of USD 4.0 million to USD 5.0 million by the end of Q2 2025, enhancing operational efficiency through integrated engagement technology and reduced reliance on third-party services. CEO Mark Newcomer emphasized the company’s focus on leveraging this acquisition to expand platform capabilities, particularly in the plasma, pharmaceutical, and healthcare sectors, while maintaining a robust pipeline to sustain its growth trajectory.
• 2025 Outlook and Future Growth Prospects: Paysign revised its full-year 2025 outlook upward, projecting total revenues of USD 72.0 million to USD 74.0 million, reflecting a 25.0% year-over-year growth at the midpoint, with patient affordability expected to contribute 43.0% of revenue (up over 135%) and plasma 57.0% (down 8.0% to 10.0%). Gross profit margins are anticipated to range between 62.0% and 64.0%, while operating expenses are lowered to USD 41.0 million to USD 43.0 million, incorporating efficiencies from the Gamma acquisition. Net income is forecasted at USD 6.0 million to USD 7.0 million, or USD 0.10 to USD 0.12 per diluted share, and Adjusted EBITDA is expected to be between USD 16.0 million and USD 17.0 million, or USD 0.28 to USD 0.30 per diluted share, reflecting confidence in continued growth, particularly in the patient affordability segment, despite plasma sector challenges. For Q2 2025, revenues are projected at USD 18.5 million to USD 19.0 million, with Adjusted EBITDA of USD 4.5 million to USD 5.0 million, maintaining strong operational momentum.

Technical Observation (on the daily chart):

The 14-day Relative Strength Index (RSI) is currently at 66.04, currently approaching towards over bought zone, with the expectations of consolidation or upward continuation if the USD 3.00- USD 3.30 resistance is broken on the upside. In addition, the current price is between both the 50-day Simple Moving Averages (SMAs) and 200-day SMA, which may work as medium to long term support and resistance levels respectively. 

As per the above-mentioned price action, recent key business and financial updates, momentum in the stock over the last month, and technical indicators analysis, a ‘WATCH’ rating has been given Paysign, Inc. (NASDAQ: PAYS) at the current price of USD 2.73, as of May 09, 2025, at 08:15 am PDT. 

Individuals can evaluate the stock based on the support and resistance levels provided in the report in case of keen interest taking into consideration the risk-reward scenario. 

Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.

Related Risk: This report may be looked at from a high-risk perspective and a recommendation is provided for a short duration. This report is solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc. 

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is May 09, 2025. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level that the stock is expected to reach as per the relative valuation method and or technical analysis taking into consideration both short-term and long-term scenarios.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.